Fig. 4: CPPTAC (BMS-CPP1) exhibits antitumor efficacy in vivo through facilitating the degradation of PD-L1. | Nature Communications

Fig. 4: CPPTAC (BMS-CPP1) exhibits antitumor efficacy in vivo through facilitating the degradation of PD-L1.

From: Targeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates

Fig. 4: CPPTAC (BMS-CPP1) exhibits antitumor efficacy in vivo through facilitating the degradation of PD-L1.

a Schematic illustration of the tumor-inhibition study and the general treatment procedure. Created in BioRender. OU, ZI. (2025) https://BioRender.com/8m9xnsp. b Body weight change curves of mice from day 6 to day 18. Data represent the mean ± SEM (n = 5 mice per group). c Tumor growth curves for each group. Comparison of the tumor size after 18 days of different treatments. Data represent the mean ± SEM (n = 5 mice per group). The statistical significance was assessed using two-way ANOVA. d Photograph of the peeled-off tumors of all four groups. e Comparison of the tumor weight after tumor dissection. Data represent the mean ± SEM (n = 5 mice per group). The statistical significance was assessed using two-tailed Student’s t-tests. f Metastasis of tumor in the spleens of each group. g Western blot analysis of PD-L1 in B16F10 tumor tissues. Densitometry was used to calculate protein levels, and data were normalized to control. Data represent the mean ± SEM (n  =  3 mice per group). Statistical significance was assessed using two-tailed Student’s t-tests. h Representative immunohistochemical staining of PD-L1 in tumor tissues. Scale bar, 50 μm. Source data are provided as a Source Data file.

Back to article page